Jove
Visualize
联系我们

相关概念视频

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

68.2K
Overview
68.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

903
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
903

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.

Blood neoplasia·2026
Same author

TRAC in vivo: culmination of CAR and vector engineering.

Cell research·2026
Same author

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.

Nature cancer·2026
Same author

Antibody S22019F Selectively Recognises KIR2DS1 and Enables Analysis of KIR2DS1<sup>+</sup> NK Cells and T Cells.

HLA·2026
Same author

Dual CAR-T cell therapy targeting CD19 and BCMA as a novel opportunity for immune reset in systemic lupus erythematosus.

Cellular & molecular immunology·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jun 28, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

195

工程免疫逃避性全原细胞免疫疗法

Karen E Martin1,2, Quirin Hammer3, Karlo Perica4,5

  • 1Precision Immunotherapy Alliance, The University of Oslo, Oslo, Norway.

Nature reviews. Immunology
|April 24, 2024
PubMed
概括

全基细胞疗法提供了有前途的癌症治疗方法,但面临免疫排斥. 受病毒和癌症免疫规避启发的策略可以改善这些现成免疫疗法的持久性.

更多相关视频

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K
HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

15.4K

相关实验视频

Last Updated: Jun 28, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

195
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.2K
HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

15.4K

科学领域:

  • 免疫学 免疫学 免疫学
  • 在瘤学瘤学.
  • 生物技术是生物技术.

背景情况:

  • 全基细胞免疫疗法为癌症治疗提供了可扩展和具有成本效益的方法.
  • 与自身治疗相比,转移的全原性T细胞和自然杀手细胞 (NK细胞) 的免疫排斥限制了它们的临床疗效.
  • 克服免疫排斥对于实现现成的基于细胞的癌症治疗的全部潜力至关重要.

研究的目的:

  • 讨论设计异性T和NK细胞以逃避免疫排斥的策略.
  • 探索病毒和癌症免疫逃生机制的使用,作为增强细胞治疗持久性的基础.
  • 突出基因组编辑和合成生物学在开发先进的基于细胞的免疫疗法的作用.

主要方法:

  • 审查病毒和癌细胞使用的免疫逃避机制.
  • 讨论基因组编辑和合成生物学方法用于细胞工程.
  • 在全原细胞疗法的背景下分析先天和适应性免疫反应.

主要成果:

  • 识别可以适应全源细胞疗法的免疫逃避策略.
  • 提高现成细胞产品的持久性和治疗窗口的潜力.
  • 强调需要考虑宿主免疫反应,以获得成功的治疗结果.

结论:

  • 具有免疫逃避性质的基因细胞工程是克服排斥障碍的关键.
  • 病毒和癌症免疫逃生机制为增强细胞治疗持久性提供了宝贵的蓝图.
  • 精密免疫疗法设计需要全面了解接受者的免疫反应,以最大限度地提高治疗效益.